Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.38 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.38 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22267911 | 0.85 | CCR3 (0.39) | PTPRBADRB3CCR3KDM4EL3MBTL1 | |
| SCHEMBL19257745 | 0.85 | CCR3 (0.39) | PTPRBADRB3CCR3KDM4EL3MBTL1 | |
| SCHEMBL18943837 | 0.85 | PTPRB (0.45) | PTPRBADRB3TAAR1SLC18A2SIGMAR1 | |
| SCHEMBL19647189 | 0.82 | PTPRB (0.48) | PTPRBADRB3SIGMAR1CCR3PKM | |
| SCHEMBL18938234 | 0.82 | ADRB3 (0.50) | PTPRBADRB3CCR3PKMKDM4E | |
| SCHEMBL23505743 | 0.81 | EPHX1 (0.49) | PTPRBADRB3TAAR1CCR3PKM | |
| SCHEMBL22267964 | 0.80 | ADRB3 (0.41) | PTPRBADRB3TAAR1SLC18A2SIGMAR1 | |
| SCHEMBL19258135 | 0.80 | ADRB3 (0.41) | PTPRBADRB3TAAR1SLC18A2SIGMAR1 | |
| SCHEMBL28087988 | 0.80 | ADRB3 (0.48) | PTPRBADRB3CCR3PKMKDM4E | |
| SCHEMBL8945778 | 0.80 | SLC6A2 (0.37) | PTPRBADRB3CCR3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081230-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11160874-B2 | Glycoengineered antibody drug conjugates | GENZYME CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210205463-A1 | STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | PFIZER INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| WO-2017134547-A1 | TUBULYSIN ANALOGS AND METHODS FOR THEIR PREPARATION | PFIZER INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160874-B2 | Glycoengineered antibody drug conjugates | CD2BP2, B3GAT3, SIGLEC7 | PTPRB 157/4885ADRB3 4589/4885TAAR1 4404/4885 |
| US-10723727-B2 | Tubulysin analogs and methods for their preparation | NGLY1, TEK, TEKT1 | PTPRB 794/4885ADRB3 2727/4885TAAR1 3354/4885 |
| US-20210205463-A1 | STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | FCGR2A, FCGRT, FCGR1A | PTPRB 203/4885ADRB3 4328/4885TAAR1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.